A strong management team and sound investment process underpin MFS Emerging Markets Debt R3's Morningstar Quantitative Rating of Bronze. Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the second-costliest quintile among peers.
- NAV / 1-Day Return 12.04 / 0.53 %
- Total Assets 7.2 Bil
-
Adj. Expense Ratio
- Expense Ratio 1.050%
- Distribution Fee Level Low
- Share Class Type Retirement, Medium
- Category Emerging Markets Bond
- Credit Quality / Interest Rate Sensitivity Low / Extensive
- Min. Initial Investment 0
- Status Open
- TTM Yield 6.55%
- Effective Duration 6.78 years
Morningstar’s Analysis MEDFX
Will MEDFX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.